E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 4/5/2021 in the Prospect News High Yield Daily.

Organon starts roadshow for $4.5 billion equivalent seven-, 10-year notes in three tranches

By Paul A. Harris

Portland, Ore., April 5 – Organon & Co. began a roadshow on Monday for a $4.5 billion equivalent offering of notes in three tranches, according to a syndicate source.

Tranches are as follows:

• $2 billion seven-year senior secured notes, callable after three years at par plus 50% of the coupon, with initial talk in the low 4% area;

• $1 billion equivalent euro-denominated seven-year senior secured notes, callable after three years at par plus 50% of the coupon, with initial talk in the low 3% area; and

• $1.5 billion 10-year senior unsecured notes, callable after five years at par plus 50% of the coupon, with initial talk in the mid-to-high 5% area.

The roadshow wraps up on Wednesday, and the Rule 144A and Regulation S for life notes are set to price on Thursday.

Left lead bookrunner Morgan Stanley & Co. LLC will bill and deliver. J.P. Morgan Securities LLC, BofA Securities Inc., BNP Paribas Securities Corp., Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC and HSBC Securities (USA) Inc. are joint bookrunners.

Mizuho Securities USA Inc., Wells Fargo Securities LLC, Barclays, RBC Capital Markets LLC, Santander Investment Securities Inc. and SG Americas Securities LLC are co-managers.

Upon release from escrow the proceeds plus cash on the balance sheet and proceeds from a term loan will be used to fund a dividend to Merck & Co., Inc., related to Organon's spinoff from Merck.

The issuing entity will be Organon Finance 1 LLC, to be assumed by Organon & Co.

The Kenilworth, N.J.-based company was created by Merck's spinoff of its women’s health, trusted legacy brands and biosimilars businesses.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.